 Hypothesis B2: During phase 2, there will be a difference between the two groups in the percentage of responders 50 or greater reduction in symptom severity with regards to painful symptoms of MDD, as measured by the overall visual analogue pain VAS-pain scale scores; response rates will be higher for the ziprasidone group. 